Search Contract Opportunities

Sentinel 3.0_2026 Updated Market Research

ID: 75F40126SSN00100 • Type: Sources Sought • Match:  100%
Opportunity Assistant

Hello! Please let me know your questions about this opportunity. I will answer based on the available opportunity documents.

Please sign-in to link federal registration and award history to assistant. Sign in to upload a capability statement or catalogue for your company

Popular Questions:
Generate a draft:
Loading

Description

The U.S. Food and Drug Administration (FDA) issues this Noitce as a means of conducting market research to inform acquisition planning in accordance with the Federal Acquisition Regulation (FAR) Parts 7 and 10. This notice is not a Request for Proposal (RFP), Request for Quotation (RFQ), or Invitation for Bid (IFB), and no award will result from this announcement.

As part of its market research, the FDA previously issued Notice FDARFI5302025. The operational framework described in that notice has since been revised. The FDA now anticipates supporting its Sentinel 3.0 programmatic requirements with the following contract structure:

Contract 1:
Sentinel 3.0 Data Partners (Tiers 1 6, previously Tiers 1 5) providing access to multiple types of healthcare data. The FDA is considering a Data Broker led acquisition model in which a prime contractor is responsible for acquiring, licensing, governing, and providing access to healthcare data across Tiers 1 6, including coordination with third-party data providers. Respondents should assume a single prime contractor retains full contractual, legal, and compliance responsibility for all data delivered under this model.

Contract 2:
Sentinel 3.0 Government-Owned, Contractor-Operated (GOCO) platform (Tier 7) serving as a data repository, enabling interoperability, and delivering informatics tools and capabilities. Uder this model, the Government will not require platform development, platform hosting, platform replacement, alternative architectures, or contractor-operated environments. All pricing responses should assume data is delivered to, accessed through, or integrated with the existing Government platform.

Contract 3:
Sentinel 3.0 Scientific Support Services (Tier 8). Provide scientific services including data analytics support (e.g., capability to conduct complex pharmacoepidemiology and pharmacovigilance studies, and advanced analytics).
Specifically, under this notice, the Government is seeking information to better understand the commercial market's capabilities to support Tiers 1 6 under a Data Broker led acquisition model for Sentinel 3.0. The Government anticipates requiring the expertise of an experienced and qualified provider to acquire, aggregate, de-identify, govern, license, and facilitate access to healthcare data across multiple data types and sources. This may include coordination and management of third-party data providers, as outlined in the draft Performance Work Statement (PWS).

See attached documents for complete notice.

Background
The U.S. Food and Drug Administration (FDA) is conducting market research to inform acquisition planning for its Sentinel 3.0 program, which aims to enhance postmarket safety surveillance capabilities as mandated by the FDA Amendments Act of 2007 (FDAAA).

The initiative seeks to establish an active risk identification and analysis system capable of monitoring the safety of FDA-regulated medical products across a population of at least 100 million individuals. The FDA has evolved its Sentinel Initiative through various phases, including Mini-Sentinel and Sentinel System versions 1.0 and 2.0, to leverage real-world healthcare data and advanced analytic methods for regulatory decision-making.

Work Details
The contract structure includes three main components:
1. **Data Broker Services (Tiers 1–6)**: The contractor will provide governed access to diverse healthcare data sources, including commercial healthcare insurance claims data, Healthcare Insurance Claims–EHR linked data, outpatient prescription data, and other relevant datasets. The contractor will be responsible for acquiring, licensing, governing, and managing access to all data assets while coordinating with third-party data providers as necessary.

2. **FDA Data Platform (Tier 7)**: This component involves utilizing a Government-developed platform that serves as a repository for data ingestion and analytics enablement without requiring platform development or hosting by the contractor. The platform will facilitate interoperability and provide analytic tools.

3. **Scientific Support Services (Tier 8)**: The contractor will offer scientific services including advanced analytics support for complex pharmacoepidemiology and pharmacovigilance studies.

Overview

Response Deadline
March 23, 2026, 10:00 a.m. EDT Past Due
Posted
March 2, 2026, 11:51 p.m. EST (updated: March 4, 2026, 6:39 p.m. EST)
Set Aside
None
PSC
None
Place of Performance
North Bethesda, MD United States
Source

Current SBA Size Standard
$40 Million
Pricing
Likely Fixed Price
Est. Level of Competition
Low
Odds of Award
29%
Vehicle Type
Indefinite Delivery Contract
On 3/2/26 Food and Drug Administration issued Sources Sought 75F40126SSN00100 for Sentinel 3.0_2026 Updated Market Research due 3/23/26. The opportunity was issued full & open with NAICS 518210.
Primary Contact
Name
Narissa Charles   Profile
Phone
(301) 796-3169

Documents

Posted documents for Sources Sought 75F40126SSN00100

Opportunity Assistant


AI Analysis

AI Generate

Incumbent or Similar Awards

Contracts Similar to Sources Sought 75F40126SSN00100

Potential Bidders and Partners

Awardees that have won contracts similar to Sources Sought 75F40126SSN00100

Similar Active Opportunities

Open contract opportunities similar to Sources Sought 75F40126SSN00100

Experts for Sentinel 3.0_2026 Updated Market Research

Recommended subject matter experts available for hire

Additional Details

Source Agency Hierarchy
HEALTH AND HUMAN SERVICES, DEPARTMENT OF > FOOD AND DRUG ADMINISTRATION > FDA OFFICE OF ACQ GRANT SVCS
FPDS Organization Code
7524-00223
Source Organization Code
100188033
Last Updated
March 4, 2026
Last Updated By
narissa.charles@fda.hhs.gov
Archive Date
April 7, 2026